Floatz logo

cb-839

KRAS Gene Mutation

Calithera Biosciences, IncPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the KRAS Gene Mutation cohort.

Asset / SponsorPhaseRating
gsk1120212
Memorial Sloan Kettering Cancer Center
Phase 2BB
Regorafenib
Stanford University
Phase 2B
METHOTREXATE
Stanford University
Phase 2B
5-azacytidine
Stanford University
Phase 2B
Palbociclib
Calithera Biosciences, Inc
Phase 1/2B

View all 30 →

Same molecule, other indications

cb-839 is also rated in:

CRCDormant
CCC
Indicative ·
48 / 100
View asset →
Waldenstrom's Macroglobulinemia (WM)Dormant
CC
Indicative ·
47 / 100
View asset →
Non-Hodgkin's Lymphoma (NHL)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →